Absci Develops Groundbreaking Machine Learning Models for In-Silico Antibody Design, Powered by NVIDIA

VANCOUVER, Wash., March 22, 2022 — Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, announced the development of machine learning models for designing and refining novel therapeutic antibodies. The new research demonstrates progress towards a fully in-silico machine learning pipeline for drug discovery.

Read the full Press Release

Learn More:

• “Absci’s Data and AI Platform for In Silico Antibody Design & Optimization” presented at NVIDIA GTC 2022 by Absci Lead AI Scientist Joshua Meier
• Absci Data Presentation, March 2022